REDHILL BIOPHAR/S (NASDAQ:RDHL) Upgraded to “Strong-Buy” by WBB Securities

REDHILL BIOPHAR/S (NASDAQ:RDHL) was upgraded by analysts at WBB Securities from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Friday, BenzingaRatingsTable reports. The firm presently has a $17.00 target price on the biotechnology company’s stock. WBB Securities’ price target points to a potential upside of 156.02% from the stock’s current price.

Several other research firms also recently weighed in on RDHL. Zacks Investment Research downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Finally, Ascendiant Capital Markets set a $23.00 price target on REDHILL BIOPHAR/S and gave the stock a “buy” rating in a research note on Monday. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. REDHILL BIOPHAR/S currently has an average rating of “Buy” and an average price target of $17.75.

REDHILL BIOPHAR/S stock opened at $6.64 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.09 and a quick ratio of 3.99. The stock has a market cap of $144.56 million, a P/E ratio of -3.91 and a beta of 1.40. The stock has a 50 day moving average of $7.05. REDHILL BIOPHAR/S has a twelve month low of $5.13 and a twelve month high of $11.49.

REDHILL BIOPHAR/S (NASDAQ:RDHL) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04. The company had revenue of $1.74 million for the quarter, compared to the consensus estimate of $2.98 million. REDHILL BIOPHAR/S had a negative return on equity of 97.62% and a negative net margin of 506.47%. Research analysts predict that REDHILL BIOPHAR/S will post -1.3 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the stock. Van ECK Associates Corp lifted its position in REDHILL BIOPHAR/S by 42.1% in the 4th quarter. Van ECK Associates Corp now owns 10,787 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 3,195 shares in the last quarter. ARK Investment Management LLC lifted its position in REDHILL BIOPHAR/S by 8.5% in the 1st quarter. ARK Investment Management LLC now owns 65,918 shares of the biotechnology company’s stock valued at $548,000 after acquiring an additional 5,177 shares in the last quarter. Menta Capital LLC lifted its position in REDHILL BIOPHAR/S by 9.4% in the 4th quarter. Menta Capital LLC now owns 93,872 shares of the biotechnology company’s stock valued at $521,000 after acquiring an additional 8,087 shares in the last quarter. Geode Capital Management LLC bought a new position in REDHILL BIOPHAR/S in the 4th quarter valued at approximately $73,000. Finally, D. E. Shaw & Co. Inc. bought a new position in REDHILL BIOPHAR/S in the 4th quarter valued at approximately $186,000. 35.48% of the stock is currently owned by institutional investors and hedge funds.

About REDHILL BIOPHAR/S

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

Read More: Resistance Level

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply